Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The purpose of this study is to evaluate the efficacy and safety of Camrelizumab in Combination With Nab-Paclitaxel and carboplatin as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC).
Epistemonikos ID: ee29e5feb2a77c4e0f966958f374abf57bfc50bb
First added on: May 08, 2024